Primary Job Title Chief Operating Officer Primary Organization 
PreciThera
LinkedIn View on LinkedIn
Philippe Crine has over 30 years experience in protein engineering and molecular endocrinology.
As cofounder and chief scientific officer of Enobia Pharma, Philippe Crine was responsible for development of new tharapies for rare bone metabolic diseases. Notably, Philippe Crine was responsible for the initiation and preclinical development of the
asfotase alfa (now Strensiq®) prior to Enobia’s acquisition by Alexion. In 2015 Strensiq received worldwide marketing approval for hypophosphatasia, an ultra-rare metabolic bone disease.
Both prior to and simultaneously with the creation of Enobia, Philippe Crine also served as full professor at the Université de Montréal Medical School, chair of the Biochemistry department and finally assistant dean for Medical Research. Under his tenure the Biochemistry department recruited four new faculty and created a structural biology group jointly with McGill University and the National Research Council of Canada.
Philippe Crine received his Ph.D from the Université de Montréal Medical School and postdoctoral training at Brandeis University (Massachusetts) and at the Clinical Research Institute of Montreal. He co-authored over 120 publications in peer reviewed scientific journals.
